BLFS
NASDAQ · Life Sciences Tools & Services
Biolife Solutions Inc
$36.69
-0.16 (-0.43%)
Financial Highlights (FY 2026)
Revenue
103.90M
Net Income
-4,960,934
Gross Margin
64.6%
Profit Margin
-4.8%
Rev Growth
-15.9%
D/E Ratio
0.01
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 64.6% | 64.6% | 54.8% | 54.8% |
| Operating Margin | -17.3% | -15.5% | 5.1% | 5.3% |
| Profit Margin | -4.8% | -4.5% | 4.6% | 6.3% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 103.90M | 123.56M | 1.26B | 1.01B |
| Gross Profit | 67.08M | 79.77M | 690.00M | 556.09M |
| Operating Income | -17,933,339 | -19,193,727 | 63.84M | 54.08M |
| Net Income | -4,960,934 | -5,309,597 | 58.21M | 63.51M |
| Gross Margin | 64.6% | 64.6% | 54.8% | 54.8% |
| Operating Margin | -17.3% | -15.5% | 5.1% | 5.3% |
| Profit Margin | -4.8% | -4.5% | 4.6% | 6.3% |
| Rev Growth | -15.9% | -15.9% | +9.5% | +17.1% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 11.92M | 11.92M | 538.01M | 550.42M |
| Total Equity | 889.25M | 889.25M | 666.68M | 636.38M |
| D/E Ratio | 0.01 | 0.01 | 0.81 | 0.86 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -17,646,900 | -19,936,443 | 80.62M | 66.64M |
| Free Cash Flow | — | — | 44.34M | 36.90M |